Table 2.

Anaphylactic reactions (A) and anaphylactic shock (Β) cases following mRNA COVID-19 vaccination in children and adolescents by vaccine brand, age group, and sex (EudraVigilance, as of October 8, 2022).

(A) Anaphylactic reactions	mRNA-1273a				BNT162b2b
Age group	Females	Males	Unknown	Total by age	Females	Males	Unknown	Total by age
0–2 years	1	0	0	1	2	1	1	4
3–11 years	0	0	0	0	21	20	1	42
12–17 years	7	6	0	13	146	84	3	233
Total by sex	8	6	0	14	169	105	5	279
(Β) Anaphylactic shock	mRNA-1273a				BNT162b2b
Age group	Females	Males	Unknown	Total by age	Females	Males	Unknown	Total by age
0–2 years	0	0	0	0	1	0	0	1
3–11 years	0	0	0	0	4	2	0	6
12–17 years	2	2	0	4	38	27	2	67
Total by sex	2	2	0	4	43	29	2	74

^aSpikevax (Moderna).

^bComirnaty (Pfizer-BioNTech).